Neupogen (Filgrastim)

Filgrastim, the active ingredient in Neupogen, is a granulocyte colony‑stimulating factor presented as a subcutaneous injectable solution for subcutaneous use. It stimulates the production and activation of neutrophil precursors, helping to restore neutrophil counts in patients who develop neutropenia due to chemotherapy, bone‑marrow transplantation, or severe chronic conditions.

GNH USA supplies Neupogen as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres and pharmacies worldwide.

Neupogen (filgrastim) acts on the hematopoietic system to increase neutrophil production in several clinical settings.

- Chemotherapy‑induced neutropenia: reduces the duration of neutropenia and lowers infection risk during cancer treatment. - Severe chronic neutropenia: raises neutrophil counts to mitigate recurrent infections in patients with congenital or acquired neutropenia. - Neutropenia following bone‑marrow transplantation: supports engraftment and accelerates hematologic recovery after transplant procedures. - Aplastic anemia (adjunct therapy): enhances neutrophil recovery when used alongside other treatments for bone‑marrow failure.

Filgrastim may cause a range of adverse reactions, from mild to serious.

Common Side Effects: - Bone pain - Injection‑site erythema or discomfort - Headache - Fatigue - Fever - Nausea

Serious or Rare Side Effects: - Splenic rupture - Acute respiratory distress syndrome - Severe allergic reactions (anaphylaxis) - Capillary leak syndrome - Marked leukocytosis with risk of vascular occlusion - Severe bone pain requiring medical intervention

Before initiating therapy, clinicians should consider several safety measures.

- Monitor blood counts: perform complete blood count before initiation and regularly during therapy. - Assess for splenomegaly: evaluate abdomen if patient reports left‑upper‑quadrant pain. - Discontinue if hypersensitivity occurs: stop treatment at first sign of allergic reaction. - Use caution in sickle‑cell disease: increased risk of vaso‑occlusive events. - Avoid in patients with active uncontrolled infection: may mask infection signs. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Filgrastim can interact with other medicines, requiring attention to avoid adverse outcomes.

Major Interactions (Avoid): - Concurrent use with other G‑CSF agents: may cause excessive neutrophil proliferation. - Combination with cytotoxic chemotherapy that has overlapping myelosuppressive effect: can intensify bone‑marrow toxicity.

Moderate Interactions (Monitor Closely): - Systemic corticosteroids: may reduce filgrastim efficacy. - Certain antibiotics (e.g., beta‑lactams): can mask infection symptoms. - Live vaccines: immune response may be diminished. - Antifungal agents (e.g., azoles): possible pharmacokinetic alterations.